2 research outputs found
Impact of systemic hypoxemia on cancer aggressiveness and circulating vascular endothelial growth factors A and C in gastroesophaeal cancer patients with chronic respiratory insufficiency
Aim: Due to the common etiologic factor, a considerable number of esophagogastric cancer patients suffer from respiratory insufficiency in course of chronic obstructive pulmonary disease, primary to cancer. Systemic hypoxemia may account for poor oxygenation of tumor tissue-a main driving force of tumor neoangiogenesis. We hypothesized that in cancer patients with respiratory insufficiency, systemic hypoxemia may be related to enhanced aggressiveness of cancer on one side and to the elevation of angiogenic factors on the other. Methods: The levels of vascular endothelial growth factors A and C were determined with immunoenzymatic methods in patients diagnosed with esophagogastric cancer with or without co-existing respiratory insufficiency in course of chronic obstructive pulmonary disease and in healthy controls. Blood gasometry and hemoglobin levels of cancer patients were related to cancer histology and TNM status, and to circulating vascular endothelial growth factors A and C. Results: Patients with systemic hypoxemia had higher incidence rates of locally advanced tumors. Partial oxygen pressure and blood oxygen saturation were significantly lowered in patients with T4 cancers as compared to less advanced onces. Circulating vascular endothelial growth factor A, but not C, was more elevated in esophagogastric cancer patients with co-existing respiratory insufficiency, as compared to those without respiratory insufficiency. Vascular endothelial growth factor A was also strongly related to the extension of primary tumor. Conclusion: Our results show that systemic hypoxemia in esophagogastric cancer patients is associated with the extension of primary tumor and that this effect might be mediated by the up-regulation of circulating vascular endothelial growth factor A.Π¦Π΅Π»Ρ: Π² ΡΠ²ΡΠ·ΠΈ Ρ ΠΎΠ±ΡΠΈΠΌ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ , Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π±ΠΎΠ»ΡΠ½ΡΡ
Π³Π°ΡΡΡΠΎΡΠ·ΠΎΡΠ°Π³Π°Π»ΡΠ½ΡΠΌ
ΡΠ°ΠΊΠΎΠΌ ΡΡΡΠ°Π΄Π°Π΅Ρ ΠΎΡ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π»Π΅Π³ΠΎΡΠ½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΊΠΎΡΠΎ-
ΡΠΎΠ΅ ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΡΠ°ΠΊΡ. Π‘ΠΈΡΡΠ΅ΠΌΠ½Π°Ρ Π³ΠΈΠΏ ΠΎΠΊΡΠ΅ΠΌΠΈΡ ΠΌΠΎΠΆΠ΅Ρ Π²Π»ΠΈΡΡΡ Π½Π° ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ ΡΡ ΠΎΠΊΡΠΈΠ³Π΅Π½Π° ΡΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎ ΠΉ ΡΠΊΠ°Π½ΠΈ β ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ
ΠΈΡΡΠΎΡΠ½ΠΈΠΊ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ Π½Π΅ΠΎΠ°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π°. ΠΠ²ΡΠΎΡΡ ΠΏΡΠ΅Π΄ΠΏ ΠΎΠ»ΠΎΠΆΠΈΠ»ΠΈ , ΡΡΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏ ΡΠΎΡΠΈΠ»Ρ Ρ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎ ΠΉ
Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ ΡΠΈΡΡΠ΅ΠΌΠ½Π°Ρ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΡ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΡΠ²ΡΠ·Π°Π½Π° Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠΉ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°, Ρ
ΠΎΠ΄Π½ΠΎΠΉ ΡΡΠΎΡΠΎΠ½Ρ, ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π½ΡΡ
ΡΠ°ΠΊΡΠΎΡΠΎΠ² β Ρ Π΄ΡΡΠ³ΠΎΠΉ. ΠΠ΅ΡΠΎΠ΄Ρ: ΡΠΎΠ΄ Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΎΡΡΠ° ΡΠ½Π΄ΠΎ-
ΡΠ΅Π»ΠΈΡ ΡΠΎΡΡΠ΄ΠΎΠ² A ΠΈ C ( VEGF ) ΠΎΠΏΡΠ΅Π΄ Π΅Π»ΡΠ»ΠΈ ΠΈΠΌΠΌΡ Π½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΌΠΈ ΠΌΠ΅ΡΠΎ Π΄Π°ΠΌΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π³Π°ΡΡΡΠΎΡΠ·ΠΎΡΠ°Π³Π°Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π½Π° ΡΠΎΠ½Π΅
ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
ΠΈΠ»ΠΈ Π² ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΠ°ΠΊΠΎΠ²ΠΎΠ³ΠΎ,
Π° ΡΠ°ΠΊΠΆΠ΅ Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ². ΠΠ½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΠΈ Π΄ Π°Π½Π½ΡΠ΅ Π³Π°Π·ΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΈ ΡΠΎΠ΄ Π΅ΡΠΆΠ°Π½ΠΈΡ Π³Π΅ΠΌΠΎΠ³Π»ΠΎΠ±ΠΈΠ½Π° Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ, ΡΡΠ°ΡΡΡΠ° TNM ΠΈ ΡΡΠΎΠ²Π½Ρ VEGF A ΠΈ C. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎ ΠΉ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΠ΅ ΠΉ ΡΠ°ΡΡΠΎΡΠ° ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΡΠ»Π° Π²ΡΡΠ΅. ΠΠ°ΡΡΠΈΠ°Π»ΡΠ½ΠΎΠ΅ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ ΠΊΠΈΡΠ»ΠΎΡΠΎ Π΄Π° ΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΊΠΈΡΠ»ΠΎΡΠΎ Π΄ ΠΎΠΌ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΎ Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠ΅ΠΉ T4. ΠΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΠ΄ Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΠΈΡΠΊΡΠ»ΠΈΡΡΡΡΠ΅Π³ΠΎ VEGF A, Π½ΠΎ Π½Π΅ C, Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½ΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠ΅ΡΠΏΠΈ-
ΡΠ°ΡΠΎΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ, ΡΠ΅ΠΌ Π±Π΅Π· Π½Π΅Π΅. Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ VEGF ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π»ΠΎ Ρ ΠΎΠ±ΡΠ΅ΠΌΠΎΠΌ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎ ΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ . ΠΡΠ²ΠΎΠ΄Ρ: Π½Π°
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ, ΡΡΠΎ ΡΠΈΡΡΠ΅ΠΌΠ½Π°Ρ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π³Π°ΡΡΡΠΎΡΠ·ΠΎΡΠ°Π³Π°Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΡΠ²ΡΠ·Π°Π½Π° Ρ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΎΠ±ΡΠ΅ΠΌΠ°
ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, ΠΈ ΡΠ°ΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΠΈΡΠΊΡΠ»ΠΈΡΡΡΡΠ΅Π³ΠΎ VEGF
Respiratory insufficiency related to copd accelerates systemic inflammation, under-nutrition, and angiogenesis in esophageal malignancies
A number of esophageal cancer patients suffer from respiratory insufficiency due to the coexistence of chronic obstructive pulmonary disease (COPD). Aim: To test the hypothesis that COPD-related systemic hypoxemia may result in accelerated inflammation, malnutrition, and angiogenesis in esophageal cancer patients. Methods: Serum levels of C-reactive protein (CRP), albumin, transferrin, interleukin-1, interleukin-6, interleukin-8, TNF- a, platelet-derived growth factor (PDGF-BB), and midkine and patient BMI and weight-loss rate were determined and compared with blood oxygenation status (pO2, SaO2) in 35 esophageal cancer patients and 42 controls. Results: The incidence of cachexia tended to be higher in patients with systemic hypoxemia (67% vs 40%, p = 0.169). Mean SaO2 level was also significantly decreased in cachectic patients (90.3 vs 93.3%, p = 0.026) and pO2 exhibited a similar trend (58.0 vs 63.4 mmHg, p = 0.120). Transferrin (234 vs 316 mg/dl, p = 0.005) and albumin (31.9 vs 37.1 mg/dl, p = 0.002) concentrations were reduced and CRP was elevated (129.9 vs 54.7 mg/l, p = 0.004) in hypoxemic patients and correlated with pO2 (r = 0.47, p = 0.016; r = 0.48, p = 0.012; r = β0.37, p = 0.064) and SaO2 (r = 0.52, p = 0.006; r = 0.53, p = 0.006; r = β0.40, p = 0.042). Interleukin-6 (9.97 vs 2.21 pg/ml, p = 0.005) and midkine (2101 vs 944 pg/ml, p < 0.001) were elevated and PDGF-BB was decreased (12.2 vs 17.3 pg x 10-6/PLT, p = 0.014) in hypoxemic compared with normoxemic patients. Interleukin-6 and midkine negatively correlated with pO2 (r = β0.44, p = 0.016; r = β0.42, p = 0.011) and SaO2 (r = β0.54, p = 0.003; r = β0.57, p < 0.0001) and PDGF-BB correlated positively (r = 0.53, p = 0.003; r = 0.44, p = 0.020). Interleukin-8 level was affected by pO2 (r = -0.55, p = 0.015) and SaO2 (r = β0.55, p = 0.018) only in hypoxemic patients. Conclusions: COPD-related systemic hypoxemia negatively affects the status of esophageal cancer patients by accelerating inflammation, under-nutrition, and angiogenesis.ΠΠ½ΠΎΠ³ΠΈΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° ΡΡΡΠ°Π΄Π°ΡΡ ΠΎΡ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈΠ·-Π·Π° ΡΠ°Π·Π²ΠΈΡΠΈΡ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ
Π»Π΅Π³ΠΎΡΠ½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (COPD). Π¦Π΅Π»Ρ: ΠΡΠΎΠ²Π΅ΡΠΈΡΡ Π³ΠΈΠΏΠΎΡΠ΅Π·Ρ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΉ ΡΠ²ΡΠ·ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΠΈ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ
Ρ COPD, Ρ ΡΡΠΈΠ»Π΅Π½ΠΈΠ΅ΠΌ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ², ΠΈΡΡΠΎΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈ Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·ΠΎΠΌ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°.
ΠΠ΅ΡΠΎΠ΄Ρ: Ρ 35 Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° ΠΈ 42 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΡΡΠΎΠ²Π΅Π½Ρ CRP, Π°Π»ΡΠ±ΡΠΌΠΈΠ½Π°, ΡΡΠ°Π½ΡΡΠ΅ΡΠΈΠ½Π°,
ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°-1, ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°-6, ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°-8, TNF-Ξ±, PDGF-BB ΠΈ ΠΌΠΈΠ΄ΠΊΠΈΠ½Π° Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ BMI ΠΈ
ΠΏΠΎΡΠ΅ΡΠΈ Π²Π΅ΡΠ° Π±ΠΎΠ»ΡΠ½ΡΡ
, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΡΠΎΠ²Π½Ρ ΠΎΠΊΡΠΈΠ³Π΅Π½Π°ΡΠΈΠΈ ΠΊΡΠΎΠ²ΠΈ (pO2
, SaO2
). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΡΠ°ΡΡΠΎΡΠ° Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ
ΠΊΠ°Ρ
Π΅ΠΊΡΠΈΠΈ Π±ΡΠ»Π° Π²ΡΡΠ΅ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΠ΅ΠΉ (67 ΠΏΡΠΎΡΠΈΠ² 40%, p = 0,169). Π‘ΡΠ΅Π΄Π½ΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ SaO2
Π±ΡΠ» ΡΠ°ΠΊΠΆΠ΅
Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΊΠ°Ρ
Π΅ΠΊΡΠΈΠ΅ΠΉ (90,3 ΠΏΡΠΎΡΠΈΠ² 93,3%, p = 0,026), Ρ ΡΠΎΠΉ ΠΆΠ΅ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠ΅ΠΉ ΠΈ Π΄Π»Ρ ΡΡΠΎΠ²Π½Ρ pO2
(58,0
ΠΏΡΠΎΡΠΈΠ² 63,4 mmHg, p = 0,120). ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΡΠ°Π½ΡΡΠ΅ΡΠΈΠ½Π° (234 ΠΏΡΠΎΡΠΈΠ² 316 ΠΌΠ³/Π΄Π», p = 0,005) ΠΈ Π°Π»ΡΠ±ΡΠΌΠΈΠ½Π° (31,9 ΠΏΡΠΎΡΠΈΠ²
37,1 ΠΌΠ³/Π΄Π», p = 0,002) Π±ΡΠ»ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½Ρ, CRP ΠΏΠΎΠ²ΡΡΠ΅Π½ (129,9 ΠΏΡΠΎΡΠΈΠ² 54,7 ΠΌΠ³/Π», p = 0,004) Ρ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²,
ΡΡΠΎ ΠΊΠΎΡΠ΅Π»Π»ΠΈΡΠΎΠ²Π°Π»ΠΎ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ pO2
(r = 0,47, p = 0,016; r = 0,48, p = 0,012; r = β0,37, p = 0,064) ΠΈ SaO2
(r = 0,52,
p = 0,006; r = 0,53, p = 0,006; r = β0,40, p = 0,042). Π£ΡΠΎΠ²Π΅Π½Ρ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°-6 (9,97 ΠΏΡΠΎΡΠΈΠ² 2,21 pg/ml, p = 0,005) ΠΈ ΠΌΠΈΠ΄ΠΊΠΈΠ½Π°
(2101 ΠΏΡΠΎΡΠΈΠ² 944 pg/ml, p < 0,001) Π±ΡΠ» ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½, Π° ΡΡΠΎΠ²Π΅Π½Ρ PDGF-BB ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½ (12,2 ΠΏΡΠΎΡΠΈΠ² 17,3 pg Γ 10-6/PLT,
p = 0,014) Ρ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΏΡΠΈ Π½ΠΎΡΠΌΠΎΠΊΡΠ΅ΠΌΠΈΠΈ. Π£ΡΠΎΠ²Π½ΠΈ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°-6 ΠΈ ΠΌΠΈΠ΄ΠΊΠΈΠ½Π°
Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΎ ΠΊΠΎΡΠ΅Π»Π»ΠΈΡΠΎΠ²Π°Π»ΠΈ Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ pO2
(r = β0,44, p = 0,016; r = β0,42, p = 0,011) ΠΈ SaO2
(r = β0,54, p = 0,003;
r = β0,57, p < 0,0001) ΠΈ ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΎ β Ρ PDGF-BB (r = 0,53, p = 0,003; r = 0,44, p = 0,020). ΠΠ° ΡΡΠΎΠ²Π΅Π½Ρ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°-8
Π²Π»ΠΈΡΠ»ΠΈ pO2
(r = β0,55, p = 0,015) ΠΈ SaO2
(r = β0,55, p = 0,018) ΡΠΎΠ»ΡΠΊΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΠ΅ΠΉ. ΠΡΠ²ΠΎΠ΄Ρ: Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ
Ρ COPD ΡΠΈΡΡΠ΅ΠΌΠ½Π°Ρ Π³ΠΈΠΏΠΎΠΊΡΠ΅ΠΌΠΈΡ Π½Π΅Π³Π°ΡΠΈΠ²Π½ΠΎ Π²Π»ΠΈΡΠ΅Ρ Π½Π° ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° Π·Π° ΡΡΠ΅Ρ ΡΡΠΊΠΎΡΠ΅Π½ΠΈΡ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ², ΠΈΡΡΠΎΡΠ΅Π½ΠΈΡ ΠΈ Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·